KYTH-105 FDA Approval Status
KYTH-105 (setipiprant) is an oral prostaglandin D2 (PGD2) receptor antagonist in development for the treatment of androgenetic alopecia (AGA), or male pattern hair loss.
Development Timeline for KYTH-105
|Sep 22, 2015||Kythera Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.